Mathieu, Chantal
Gillard, Pieter
Benhalima, Katrien
Article History
First Online: 21 April 2017
Competing interests
: C.M. serves or has served on the advisory panel for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Intrexon, Janssen Pharmaceuticals, Hanmi Pharmaceuticals, Mannkind, Medtronic, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk, Pfizer, Sanofi, Roche Diagnostics and UCB. KU Leuven has received research support for C.M. from Abbott, Eli Lilly and Company, Intrexon, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk, Roche Diagnostics and Sanofi. C.M. serves or has served on the speakers bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharp and Dohme, Novartis, Novo Nordisk and Sanofi. P.G. has served on the advisory panel for AstraZeneca, Lilly, Merck Sharp and Dohme Ltd., Novo Nordisk and Sanofi. P.G. has served on the speakers bureau for AstraZeneca, Bristol-Meyers Squibb, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Novartis, Novo Nordisk and Sanofi. K.B. has served on the advisory panel for AstraZeneca, Merck Sharp and Dohme Ltd. and Novo Nordisk. K.B. has served on the speakers bureau for AstraZeneca, Bristol-Meyers Squibb, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Novartis and Novo Nordisk. KU Leuven has received research grants for K.B. from AstraZeneca, Janssen Pharmaceuticals, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk and Sanofi.